Christian Brandl

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Ralf C. Bargou, Eugen Leo, Gerhard Zugmaier et al. · Science · 2008 · 1.1K citations

Immunology, Immunoediting, Cancer Patients +18

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger, Christian Brandl, Gerhard Zugmaier et al. · Blood · 2012 · 459 citations

Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody

Torsten Dreier, Grit Lorenczewski, Christian Brandl et al. · International Journal of Cancer · 2002 · 349 citations · Full text

Immunology, Immunologic Mechanism, Cd4 T Cell Responses +19

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct

Patrick Hoffmann, Robert Hofmeister, Klaus Brischwein et al. · International Journal of Cancer · 2005 · 342 citations · Full text

Cytotoxic T Cells, Immunology, Immunoediting +17

Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

Min Zhu, Benjamin Wu, Christian Brandl et al. · Clinical Pharmacokinetics · 2016 · 203 citations

Bispecific T-cell Engager, Tumor Immunology, Cancer Immunosurveillance +8